GlassScriptPhysician profile
Mohammad Walid Kassem
NPI 1538664073
$4,128.74
in general payments reported to CMS, 2019-2025
22 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $17.86 · 2021: $758 · 2022: $792 · 2023: $198 · 2024: $1,689 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569 · Travel and Lodging: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.06 |
| Travel and Lodging | $880.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,455.45 | 2024-2025 | Linq II |
| Ceribell, INC. | $572.18 | 2022 | |
| Biogen, INC. | $326.77 | 2021-2022 | |
| Ucb, INC. | $223.95 | 2024-2025 | Briviact, Nayzilam |
| W. L. Gore & Associates, INC. | $189.08 | 2025 | Gore Cardioform Septal Occluder |
| Alexion Pharmaceuticals, INC. | $136.33 | 2019-2021 | |
| Emd Serono, INC. | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.84 | 2025 | Hyqvia |
| Amgen INC. | $123.48 | 2024 | Repatha |
| Csl Behring | $115.32 | 2022 | |
| Allergan, INC. | $111.59 | 2021 | |
| Genentech USA, INC. | $96.20 | 2019 | |
| Roche Diagnostics Corporation | $87.46 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $85.45 | 2021 | |
| Pfizer INC. | $85.16 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $77.42 | 2023 | Cerebase |
| Abbvie INC. | $53.12 | 2022-2023 | |
| Chiesi USA, INC. | $41.68 | 2021-2025 | Cleviprex |
| Biohaven Pharmaceuticals, INC. | $37.79 | 2021 | |
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Lilly USA, LLC | $17.86 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kassem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.